Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Novo Nordisk A/S
Study ID
NCT07220759
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cagrilintide — DRUG
    Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
  • Placebo (matched to Cagrilintide) — DRUG
    Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Study Details

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

Key Dates

Start date
Nov 5, 2025
Status verified
Apr 2026
Primary completion
May 12, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
330 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cagrilintide
    Participants will receive cagrilintide subcutaneously once weekly for 64 weeks.
  • Placebo Comparator: Placebo
    Participants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.

Primary Outcome Measure

Relative change in body weight [ Time Frame: From baseline (week 0) to end of treatment (week 64) ]

Locations (21)

FacilityCityStateZIPSite coordinators
Univ of Alabama_BirminghamBirminghamAlabama35294-
Chambliss Clinical Trials, LLCMontgomeryAlabama36106-
Elite Clinical Network - TucsonTucsonArizona85704-
Scripps Whittier Diabetes InstLa JollaCalifornia92037-
Clinical Trials ResearchLincolnCalifornia95648-
Pacific Clinical StudiesLos AlamitosCalifornia90720-
Walgreens - Store 4442KissimmeeFlorida34746-
Optimal Research SitesOrange CityFlorida32763-
Center for Diab,Obes & MetabPembroke PinesFlorida33024-
Palm Beach Research CenterWest Palm BeachFlorida33409-
East West Med Res InstHonoluluHawaii96814-
MediSphere Medical RCEvansvilleIndiana47714-
Walgreens - Store 3915Las VegasNevada89146-
Chear Center LLCThe BronxNew York10455-
Centricity Res New Bern MultispecialityNew BernNorth Carolina28562-
AccellacareWilmingtonNorth Carolina28401-
Spartanburg Medical ResearchSpartanburgSouth Carolina29303-
Holston Medical Group_BristolBristolTennessee37620-
Velocity Clinical Res-DallasDallasTexas75230-
TPMG Clinical ResearchNewport NewsVirginia23606-
National Clin Res Inc.RichmondVirginia23294-

Find similar trials in Birmingham, AL

By condition
Obesity / overweightType 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Univ of Alabama_Birmingham· Birmingham, ALChambliss Clinical Trials, LLC· Montgomery, ALElite Clinical Network - Tucson· Tucson, AZScripps Whittier Diabetes Inst· La Jolla, CAClinical Trials Research· Lincoln, CAPacific Clinical Studies· Los Alamitos, CA

Related Studies